Document is current
Any future updates will be listed below
-
Authors
Hammami, M Bakri https://orcid.org/0000-0003-3422-5163
Qasim, Asma
Thakur, Rahul
Vegivinti, Charan Thej Reddy
Patton, Caroline Delbourgo
Vikash, Sindhu
Kumar, Abhishek
- License Information
-
More Information
Article History
Received: 27 April 2023
Accepted: 9 July 2023
First Online: 19 July 2023
Declarations
:
: The Albert Einstein College of Medicine Institutional Review Board (IRB) determined that the study did not require IRB approval. A written consent was obtained from the patient that was reported from our institution before initiating the study.
: MBH, RT, CV, AQ, CDQ, and SV: no disclosures. AK: Dr. AK has stock investment in ABBV, ACADia Pharma, ADMA, Biologics, AGNEUS, AIKIDO, AMGEN, AVEO Pharma, Astrazeneca, Biotelemetry Inc, Bristol Meyer, Bio-Path Holdings, BeyondSpring Inc., Cara Therapeutics, ChemBio Diagnostics, Contrafect Corp, Cardiff Oncology, CRISPR Therapeutics, CVS Health, Precision Biosciences, EDITAS Medicine Inc., Five Prime Therapeutics, Globus Medicine Inc., IDEXX Laboratories, Iovance Biosciences, Johnson and Johnson, ELiLilly, Northwest Bio, PFIZER, POSEIDA Therapeutics, PTC Therapeutics, Spectrum Pharmaceuticals Inc., Viking Therapeutics, and Vertex Pharmaceuticals.
